



(51) International Patent Classification:

A61K 31/395 (2006.01) C07D 495/02 (2006.01)
C07D 209/02 (2006.01) C07D 209/42 (2006.01)
C07D 209/04 (2006.01) C07D 495/04 (2006.01)
C07D 209/30 (2006.01) A61K 31/33 (2006.01)

12730 High Bluff Drive, Suite 400, San Diego, California 92130 (US). **ANDRES, Patricia**; 12730 High Bluff Drive, Suite 400, San Diego, California 92130 (US). **DENG, Xiaohu**; 12730 High Bluff Drive, Suite 400, San Diego, California 92130 (US).

(21) International Application Number:

PCT/US2024/038216

(74) Agent: **WORMALD, Michael** et al.; WILSON SONSINI GOODRICH & ROSATI, 650 Page Mill Road, Palo Alto, California 94304 (US).

(22) International Filing Date:

16 July 2024 (16.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/514,089 17 July 2023 (17.07.2023) US
63/655,384 03 June 2024 (03.06.2024) US

(71) Applicant: **KURA ONCOLOGY, INC.** [US/US]; 12730 High Bluff Drive, Suite 400, San Diego, California 92130 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(72) Inventors: **BAKALE, Roger Paul**; 12730 High Bluff Drive, Suite 400, San Diego, California 92130 (US). **BOWE, Craig Michael**; 12730 High Bluff Drive, Suite 400, San Diego, California 92130 (US). **SENGUPTA, Dipanjan**;

(54) Title: CRYSTALLINE FORMS OF A MENIN INHIBITOR




FIGURE 1

(57) Abstract: Described herein are crystalline forms of (S)-4-methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile or solvate thereof.

[Continued on next page]

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*

(88) Date of publication of the international search report:

03 April 2025 (03.04.2025)